OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update

Nantes, France, September 28, 2026 — 7:30am CET — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today reported its cash position as of June 30, 2026, updated i…